We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

BETA CATENIN MARKET ANALYSIS

Beta Catenin Market, by Type (BBI-801, Exisulind, M-101, Nefopam Hydrochloride, and Others), by Application (Dermatology ,Oncology ,Genetic Disorder, and Others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and  Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

  • Published In : Sep 2022
  • Code : CMI5258
  • Pages :156
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Β-catenin is a multifunctional protein that is essential for preserving physiological homeostasis. A variety of illnesses, including cancer, are caused by its aberrantly high expression. The human equivalent of the drosophila armadillo gene is called β-catenin. It serves as an adapter protein for intracellular adhesion as well as a transcriptional co-regulator.

Global beta catenin market is estimated to be valued at US$ 2,492.0 million in 2022 and is expected to exhibit a CAGR of 9.6 % during the forecast period (2022-2030).

Figure 1.Global Beta Catenin Market Share (%) in Terms of Value, by Type, 2022

BETA CATENIN MARKET

To learn more about this report, request sample copy

Rise in the incidence of genetic disorders is expected to drive growth of the beta catenin market.

Rise in the incidence of genetic disorders is expected to drive growth of the beta catenin market. For instance, according to data published on May 2022, by Centers for Disease Control and Prevention (CDC), Sickle Cell Disease (SCD) affects approximately 100,000 Americans every year.

Beta Catenin Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 2,492.0 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.6 % 2030 Value Projection: US$ 5,201.5 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: BBI-801, Exisulind, M-101, Nefopam Hydrochloride, Others
  • By Application: Dermatology, Oncology, Genetic Disorder, Others
Companies covered:

Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC

Growth Drivers:
  • Increasing number of genetic disorders
  • Increase in approval of gene therapies
Restraints & Challenges:
  • High cost involved in the treatment of cancer

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Figure 2. Global Beta Catenin Market Share (%), By Region, 2022

BETA CATENIN MARKET

To learn more about this report, request sample copy

Increase in approval of gene therapies drugs is expected to drive the market growth during the forecast period.

Increase in approval of gene therapies drugs is expected to drive the market growth during the forecast period. For instance, in May 2019, the U.S Food and Drug Administration (FDA) approved Zolgensma, for the treatment of pediatric patients less than two years of age with a specific type of spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Global Beta Catenin Market– Impact of Coronavirus (COVID-19) Pandemic

COVID-19 has created significant difficulties for the world economy in addition to placing a great deal of strain on the medical system. COVID-19 has created significant difficulties for the world economy in addition to placing a significant amount of strain on the medical system. Due to the effect on different diagnoses, therapies, and research and development that were all focused on working for COVID-19, the catenin beta market was impacted. Catenin beta demand was lower than the catenin beta market's revenue, which also decreased. the COVID-19 pandemic due to the catenin beta market's use in a number of medical fields, such as dermatology, oncology, and genetic disorders for the treatment of various diseases as well as in the development of a number of medications.

Global Beta Catenin Market: Restraint

The major factors that are expected to hinder growth of the global beta catenin market include high cost involved in the treatment of cancer. For instance, according to data published on April 2022, by National Cancer Institutewhich is the federal government's principal agency for cancer research and training, states that  the average cost of medical care and drugs can cost up to US $42,000 in the year following a cancer diagnosis. Some treatments can exceed $1 million.

Key Players

Major players operating in the global beta catenin market include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc.,Propanac Biopharma Inc, Warp Drive Bio Inc.,prism pharma co ltd,aileron therapeutics inc, MD2 Biosciences Inc,WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC.

Share

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global Beta Catenin Market size was valued at USD 2,492.0 million in 2022 and is expected to reach USD 5,201.5 million in 2030.

Global beta catenin market size is estimated to be valued at US$ 2,492.0 million in 2022 and is expected to exhibit a CAGR of 9.6 % between 2022 and 2030.

Factors such as increase in the number of genetic disorders & increase in approval of gene therapies are expected to drive the market growth over the forecast period.

North America is expected to hold a major market share during the forecast period.

The major factor hampering growth of the market is high cost involved in the treatment of cancer.

Major players operating in the market include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC.
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.